全文获取类型
收费全文 | 69990篇 |
免费 | 4786篇 |
国内免费 | 2543篇 |
专业分类
耳鼻咽喉 | 305篇 |
儿科学 | 942篇 |
妇产科学 | 1020篇 |
基础医学 | 11768篇 |
口腔科学 | 949篇 |
临床医学 | 4166篇 |
内科学 | 11121篇 |
皮肤病学 | 1049篇 |
神经病学 | 10461篇 |
特种医学 | 850篇 |
外国民族医学 | 19篇 |
外科学 | 4182篇 |
综合类 | 7539篇 |
现状与发展 | 7篇 |
预防医学 | 1660篇 |
眼科学 | 604篇 |
药学 | 13104篇 |
6篇 | |
中国医学 | 1468篇 |
肿瘤学 | 6099篇 |
出版年
2024年 | 128篇 |
2023年 | 822篇 |
2022年 | 1479篇 |
2021年 | 2056篇 |
2020年 | 1805篇 |
2019年 | 1812篇 |
2018年 | 1901篇 |
2017年 | 1916篇 |
2016年 | 2004篇 |
2015年 | 2321篇 |
2014年 | 3822篇 |
2013年 | 5168篇 |
2012年 | 3804篇 |
2011年 | 4402篇 |
2010年 | 3666篇 |
2009年 | 3730篇 |
2008年 | 4043篇 |
2007年 | 3688篇 |
2006年 | 3198篇 |
2005年 | 2752篇 |
2004年 | 2572篇 |
2003年 | 2405篇 |
2002年 | 1904篇 |
2001年 | 1651篇 |
2000年 | 1496篇 |
1999年 | 1323篇 |
1998年 | 1503篇 |
1997年 | 1390篇 |
1996年 | 1268篇 |
1995年 | 1011篇 |
1994年 | 917篇 |
1993年 | 816篇 |
1992年 | 614篇 |
1991年 | 564篇 |
1990年 | 426篇 |
1989年 | 360篇 |
1988年 | 307篇 |
1987年 | 279篇 |
1986年 | 294篇 |
1985年 | 361篇 |
1984年 | 301篇 |
1983年 | 187篇 |
1982年 | 247篇 |
1981年 | 192篇 |
1980年 | 136篇 |
1979年 | 78篇 |
1978年 | 59篇 |
1977年 | 42篇 |
1976年 | 35篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
用放射配体结合分析法分别测定了正常组、特布他林组、特布他林十曲尼司特组豚鼠的肺组织β受体最大结合力和解离常数,结果显示:给特布他林后豚鼠肺组织β受体发生明显的向下调节.曲尼司特可预防此向下调节的发生. 相似文献
12.
P. A. Milligan P. E. McGill C. W. Howden A. W. Kelman B. Whiting 《European journal of clinical pharmacology》1993,45(6):507-512
Summary A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine.Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L–1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period).A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation.No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations. 相似文献
13.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
14.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc. 相似文献
15.
16.
Nerve growth factor (NGF) and NGF receptors were measured in cortex and hippocampus of rats treated with drugs affecting cholinergic neurotransmission. High (Kd= 0.045nM) and low (Kd= 21nM) affinity125I-NGF binding sites were present in both cortical and hippocampal membranes with hippocampus containing higher numbers of both sites than cortex. Chronic treatment of rats with the muscarinic receptor antagonist scopolamine (5 mg/kg, twice daily) decreased the density of high- and low-affinity sites by 50–90% in cortical and hippocampal membranes. These changes were seen after 7 days, but not 3 days, of scopolamine treatment. Chronic infusion of physostigmine (1 mg/kg/day) using minipumps increased the number of high- and low-affinity sites in cortex 3- and 6-fold, respectively. The changes in receptor-binding parameters induced by physostigmine were transient as they were evident after 3 days of treatment, but returned to control levels after 7 days. NGF content in cortex and hippocampus was reduced by about 50% following 7, but not 3, days of chronic physostigmine infusion. In contrast, scopolamine treatment failed to change NGF levels in the cholinergic neuronal target regions but it decreased NGF content in the septal area. The content of NGF mRNA in the cortex measured by Northern blot analysis failed to change following either scopolamine or physostigmine treatment. The results suggest that levels of NGF and NGF receptors in the target regions of cholinergic neurons are regulated by the extent of cholinergic neurotransmitter activity. 相似文献
17.
18.
19.
20.
子宫腺肌症病变中雌激素、孕激素、癌基因、凋亡抑制基因的表达研究 总被引:1,自引:1,他引:0
目的 研究雌激素(ER)、孕激素(PR)及癌基因(cerbB-2)、凋亡抑制基因(Bcl-2)在子宫腺肌症病变中的表达和子宫腺肌症发病的相关性。方法 用免疫组化方法检测40例子宫腺肌症病变组织中ER及其他生物学指标的表达。结果 ER、PR与CerbB.2、Bcl-2在子宫腺肌症病变中均有不同程度的阳性表达,子宫肌层异位内膜ER阳性表达率97.5%,PR阳性率97.5%,cerbB-2阳性率82.5%,Bcl-2阳性率62.5%。在位内膜和异位内膜ER、PR均呈阳性,阳性率比较差异无统计学意义(P〉0.05)。异位内膜cerbB-2的强阳性率高于在位内膜,差异有统计学意义(P〈0.05)。ER、PR与cerbB-2、Bcl-2阳性率相比具有相关性(P〈0.05)。结论 ER、PR与cerbB.2、Bcl-2在异位内膜高表达,提示这些生物学指标在子宫腺肌症发生发展中发挥作用。 相似文献